Literature DB >> 31965346

Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release.

Veronika Schmitt1,2, Claudia Kesch1, John K Jackson2, Samir Bidnur1, Eliana Beraldi1, Virginia Yago1, Mary Bowden1, Martin E Gleave3.   

Abstract

PURPOSE: We describe the preparation of injectable polymeric paste (IPP) formulations for local and sustained release of drugs. Furthermore, we include the characterization and possible applications of such pastes. Particular attention is paid to characteristics relevant to the successful clinical formulation development, such as viscosity, injectability, degradation, drug release, sterilization, stability performance and pharmacokinetics.
METHODS: Paste injectability was characterized using measured viscosity and the Hagen-Poiseuille equation to determine injection forces. Drug degradation, release and formulation stability experiments were performed in vitro and drug levels were quantified using HPLC-UV methods. Pharmacokinetic evaluation of sustained-release lidocaine IPPs used five groups of six rats receiving increasing doses subcutaneously. An anti-cancer formulation was evaluated in a subcutaneous tumor xenograft mouse model.
RESULTS: The viscosity and injectability of IPPs could be controlled by changing the polymeric composition. IPPs demonstrated good long-term stability and tunable drug-release with low systemic exposure in vivo in rats. Preliminary data in a subcutaneous tumor model points to a sustained anticancer effect.
CONCLUSIONS: These IPPs are tunable platforms for local and sustained delivery of drugs and have potential for further clinical development to treat a number of diseases.

Entities:  

Keywords:  cancer; local treatment; pain; polymer; sustained-release

Mesh:

Substances:

Year:  2020        PMID: 31965346     DOI: 10.1007/s11095-019-2730-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  45 in total

1.  Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Johns Hopkins University, Baltimore; University of Wisconsin Carbone Cancer Center; School of Medicine and Public Health; Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Mayo Clinic, Rochester, MN; University Hospitals Case Medical Center, Seidman Cancer Center; Cleveland Clinic Taussig Cancer Institute; Both in Cleveland; University of Virginia Cancer Center, Charlottesville; Comprehensive Cancer Centers of Nevada, Las Vegas; Siteman Cancer Center, Washington University School of Medicine, St. Louis; NorthShore University Health System, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor; Rutgers Cancer Institute of New Jersey, New Brunswick.N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747.

Authors:  Eggener Scott
Journal:  Urol Oncol       Date:  2017-02-01       Impact factor: 3.498

Review 2.  Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?

Authors:  Andreas Baumann; Dietrich Tuerck; Saileta Prabhu; Leslie Dickmann; Jennifer Sims
Journal:  Drug Discov Today       Date:  2014-06-11       Impact factor: 7.851

3.  The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.

Authors:  J K Jackson; M E Gleave; V Yago; E Beraldi; W L Hunter; H M Burt
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

4.  Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

Authors:  N Sato; M E Gleave; N Bruchovsky; P S Rennie; S L Goldenberg; P H Lange; L D Sullivan
Journal:  J Steroid Biochem Mol Biol       Date:  1996-05       Impact factor: 4.292

5.  Degradation of poly(lactide-co-glycolide) (PLGA) and poly(L-lactide) (PLLA) by electron beam radiation.

Authors:  J S C Loo; C P Ooi; F Y C Boey
Journal:  Biomaterials       Date:  2005-04       Impact factor: 12.479

Review 6.  The role of Gliadel wafers in the treatment of high-grade gliomas.

Authors:  Amade Bregy; Ashish H Shah; Maria V Diaz; Hayley E Pierce; Philip L Ames; Daniel Diaz; Ricardo J Komotar
Journal:  Expert Rev Anticancer Ther       Date:  2013-12       Impact factor: 4.512

Review 7.  Poly(ethylene glycol)-poly(lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications.

Authors:  Amit Alexander; Junaid Khan; Swarnlata Saraf; Shailendra Saraf
Journal:  J Control Release       Date:  2013-10-18       Impact factor: 9.776

8.  Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.

Authors:  Hirenkumar K Makadia; Steven J Siegel
Journal:  Polymers (Basel)       Date:  2011-08-26       Impact factor: 4.329

9.  A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice.

Authors:  J K Jackson; W Min; T F Cruz; S Cindric; L Arsenault; D D Von Hoff; D Degan; W L Hunter; H M Burt
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  A Thixotropic Polyglycerol Sebacate-Based Supramolecular Hydrogel as an Injectable Drug Delivery Matrix.

Authors:  Hongye Ye; Cally Owh; Shan Jiang; Cavin Zhen Quan Ng; Daniel Wirawan; Xian Jun Loh
Journal:  Polymers (Basel)       Date:  2016-04-07       Impact factor: 4.329

View more
  3 in total

Review 1.  Role of different types of nanomaterials against diagnosis, prevention and therapy of COVID-19.

Authors:  Ferial Ghaemi; Amirhassan Amiri; Mohd Yazid Bajuri; Nor Yuliana Yuhana; Massimiliano Ferrara
Journal:  Sustain Cities Soc       Date:  2021-05-25       Impact factor: 7.587

Review 2.  SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches.

Authors:  Ramalingam Karthik Raja; Phuong Nguyen-Tri; Govindasamy Balasubramani; Arun Alagarsamy; Selcuk Hazir; Safa Ladhari; Alireza Saidi; Arivalagan Pugazhendhi; Arulandhu Anthoni Samy
Journal:  Appl Nanosci       Date:  2021-06-10       Impact factor: 3.869

Review 3.  Antiviral therapies: advances and perspectives.

Authors:  Bruna Carolina Gonçalves; Mário Gabriel Lopes Barbosa; Anna Paula Silva Olak; Natalia Belebecha Terezo; Leticia Nishi; Maria Angélica Watanabe; Poliana Marinello; Daniele Zendrini Rechenchoski; Sergio Paulo Dejato Rocha; Lígia Carla Faccin-Galhardi
Journal:  Fundam Clin Pharmacol       Date:  2020-11-08       Impact factor: 2.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.